FDG-PET in Hodgkin lymphoma;FDG-PET beim Hodgkin-lymphom

NuklearMedizin

Volumn 47, Issue 6, 2008, Pages 235-238

  Kobe, Carsten ^a   Dietlein, M ^a   Mauz Korholz C ^b   Engert, A ^a   Borchmann, P ^a   Sabri, O ^c   Schober, O ^d   Schicha, H ^a   Kluge, R ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chemotherapy; Hodgkin lymphoma; PET; Radiotherapy; Response adapted design

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57349155019     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0216     Document Type: Review

References (40)

1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
2. Beyer T, Pietrzyk U, Knoess C et al. Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin 2008; 47: 73-79.
3. Bhatia S, Robinson LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
4. 18F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma - An analysis of 193 patient studies. Nuklearmedizin 2006; 45: 105-110.
5. Buchmann I, Hansen T, Brochhausen C et al. FDG-PET in the initial staging of squamous cell oesophageal carcinoma. Nuklearmedizin 2006; 45: 235-241.
6. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
7. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
8. Diehl V. Hodgkin disease - from pathology specimen to cure. N Engl J Med 2007; 357: 1968-1971.
9. Diehl V, Franklin J, Pfreundschuh M et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. N Engl. J Med 2003; 348: 2386-2395.
10. Döbert N, Kovács AF, Menzel C et al. FDG uptake after intraarterial chemotherapy in head and neck cancer. Nuklearmedizin 2006; 45: 243-247.
11. Dose-Schwarz J, Mahner S, Schirrmacher S et al. Detection of metastases in breast cancer patients - Comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen. Nuklearmedizin 2008; 47: 97-103.
12. Franzius C, Dietlein M, Biermann M et al. Procedure guideline for radioiodine therapy and 131I whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007; 46: 224-231.
13. Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology? Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
14. Gallamini A, Hutchings M, Avigdor A et al. Early interim PET scan in Hodgkin Lymphoma: where do we stand? Leuk Lymphoma 2008; 49: 659-662.
15. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
16. Jost L. Hodgkin's disease: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2007; 18 (suppl 2): ii53-ii54.
17. Juergens KU, Oei ML,Weckesser M et al.Whole-body imaging of oncologic patients using 16-channel PET-CT - Evaluation of an IV contrast enhanced MDCT protocol. Nuklearmedizin 2008; 47: 30-36.
18. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
19. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood 2006; 107: 52-59.
20. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008. DOI 10.1182/blood-2008-06-155820
21. Körholz D, Claviez A, Hasenclever D et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156.
22. 18F-fluorodeoxy-D-2-glucose positron emission tomography for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence. Onkologie 2003; 26: 489-493.
23. Krause BJ, Beyer T, Bockisch A et al. FDG-PET/CT in oncology - German Guideline. Nuklearmedizin 2007; 46: 291-301.
24. Krohn T, Kaiser H-J, Gagel B et al. 3D volume and SUV analysis of oncological PET studies. Nuklearmedizin 2007; 46: 141-148.
25. Krüger S, Pauls S, Mottaghy FM et al. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. Nuklearmedizin 2007; 46: 239-243.
26. La Fougère, Pfluger T, Schneider V et al. Restaging of patients with lymphoma. Nuklearmedizin 2008; 47: 37-42.
27. Markova J, Skopalova M, Kobe C et al. FDG-PET for Assessment of early therapy response after 4 cycles of chemotherapy in advanced stage Hodgkin Lymphoma.Ann Oncol 2008; 19: iv135.
28. Martínez M-J, Bercier Y, Schwaiger M et al. PET/CT Biograph TM Sensation 16 - Performance improving using faster electronics. Nuklearmedizin 2006; 45: 126-133.
29. Naumann R, Beuthien-Baumann B, Reiss A et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90: 620-625.
30. 18F-FDG PET/CT. Nuklearmedizin 2007; 46: 9-14.
31. Picardi M, De Renzo A, Pane F et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with postchemotherapy negative positron emission tompgraphy scans. Leuk Lymphoma 2007; 48: 1721-1727.
32. Rigacci L, Vitolo U, Nassi L et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007; 86: 897-903.
33. 18F-FDG-PET and CT: Additional diagnostic information in melanoma patients. Nuklearmedizin 2006; 45: 88-95.
34. Schaefer NG, Taverna C, Strobel K et al. Hodgkin Disease: Diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed? Radiology 2007; 244: 257-262.
35. Schicha H., Schober O. Nuklearmedizin: Basiswissen und klinische Anwendung. 5. Aufl. Stuttgart: Schattauer 2003; p81f.
36. 18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
37. 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008; 35: 1581-1588.
38. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934.
39. Wolz G, Nömayr A, Hothorn T et al. Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET. Nuklearmedizin 2007; 46: 43-48.
40. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.